UroGen Pharma Ltd. — Director's Dealing 2021

Feb 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2021-01-31

Reporting Person: Smith Jason Drew (General Counsel)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-31	Stock Option (right to buy)	$22.07	A	8000	Acquired	2031-01-30	Ordinary Shares (8000)	Direct
2021-01-31	Restricted Stock Units	$	A	2500	Acquired		Ordinary Shares (2500)	Direct

Footnotes

F1: 1/3 of the shares underlying the stock option will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024.

F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024.